Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
Beta 1.94: the stock has moved about 94% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPrecidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) trades at $20.99. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NVOH: NVOH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) Healthcare & Pipeline Overview
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged is a non-diversified fund investing primarily in ADRs of Novo Nordisk A/S, a leading global healthcare company focused on diabetes care and other serious chronic diseases. The fund provides investors exposure to Novo Nordisk's performance through ADRs.
What Is the Investment Thesis for NVOH?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) offers a focused investment opportunity tied directly to the performance of Novo Nordisk A/S, a leader in diabetes care and other chronic diseases. The fund's value is intrinsically linked to Novo Nordisk's ability to maintain its market position, innovate in its core therapeutic areas, and expand into new markets. Key value drivers include Novo Nordisk's pipeline of new drugs, its ability to navigate regulatory landscapes, and its success in managing competition from biosimilars. The fund's non-diversified nature concentrates risk, making it sensitive to any adverse events affecting Novo Nordisk, such as clinical trial failures or significant patent expirations. Investors may want to evaluate Novo Nordisk's growth prospects, particularly in emerging markets, and its ongoing efforts to diversify its product portfolio beyond insulin. The fund's beta of 1.94 suggests higher volatility compared to the broader market.
Based on FMP financials and quantitative analysis
NVOH Key Highlights
NVOH invests at least 95% of its net assets in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares), providing focused exposure.
- The fund is non-diversified, meaning its performance is highly dependent on the success of a single company, Novo Nordisk A/S.
- Novo Nordisk A/S is a global healthcare company specializing in diabetes care and other serious chronic diseases.
- NVOH's performance is directly linked to Novo Nordisk's ability to innovate, maintain market share, and navigate regulatory challenges.
- The fund's beta of 1.94 indicates higher volatility compared to the overall market.
Who Are NVOH's Competitors?
NVOH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $361.65 | +1.00% | $38.7B | — |
| DMRA Galecto, Inc. | $20.22 | -2.08% | $1.24B | — |
| CGEM Cullinan Therapeutics, Inc. | $16.04 | +3.42% | $986M | — |
| HITI High Tide Inc. | $2.63 | -1.50% | $231M | — |
| LFMDP LifeMD, Inc. | $22.86 | +0.53% | $156M | — |
| PETS PetMed Express, Inc. | $1.33 | -2.21% | $28.4M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | — |
| KYNB Kyntra Bio, Inc. | $6.09 | -3.49% | $24.7M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVOH's Key Strengths?
Focused investment strategy.
- Exposure to a leading global healthcare company.
- Potential for high returns based on Novo Nordisk's performance.
What Are NVOH's Weaknesses?
Non-diversified nature increases risk.
- Performance is entirely dependent on a single company.
- Susceptible to regulatory and market risks affecting Novo Nordisk.
What Are the Key Risks for NVOH?
Patent expirations and biosimilar competition affecting Novo Nordisk's revenue.
- Regulatory setbacks or adverse clinical trial results for Novo Nordisk's products.
- Economic downturns impacting healthcare spending and pharmaceutical sales.
- Dependence on a single company (Novo Nordisk) for fund performance.
- Market volatility affecting the value of Novo Nordisk's shares.
What Threats Does NVOH Face?
- Competition from other pharmaceutical companies.
- Patent expirations and biosimilar competition.
- Regulatory changes and healthcare policy shifts.
- Adverse events affecting Novo Nordisk's operations or reputation.
What Are NVOH's Competitive Advantages?
- Focused investment strategy providing unique exposure to Novo Nordisk A/S.
- Access to Novo Nordisk's growth and innovation in the diabetes care market.
- ADR structure simplifies investment for US-based investors.
What Does NVOH Do?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) is a specialized investment vehicle designed to provide investors with exposure to Novo Nordisk A/S (B Shares) through American Depositary Receipts (ADRs). Established to offer a targeted investment strategy, the fund operates under the Precidian ETFs Trust umbrella, focusing exclusively on Novo Nordisk ADRs. The fund invests at least 95% of its net assets in these ADRs, making it a highly concentrated investment. Unlike diversified funds, NVOH does not spread its investments across multiple companies or sectors, instead, it is specifically linked to the performance of Novo Nordisk A/S. Novo Nordisk A/S, the underlying company, is a global healthcare leader headquartered in Bagsværd, Denmark. It is renowned for its pioneering work in diabetes care, as well as its contributions to the treatment of other serious chronic conditions such as obesity, hemophilia, and growth disorders. Novo Nordisk's history is rooted in the discovery of insulin in 1923, and since then, the company has been at the forefront of developing innovative pharmaceutical products and delivery systems. NVOH offers investors a way to participate in the financial performance of Novo Nordisk without directly purchasing the company's shares on the Copenhagen Stock Exchange. The fund's performance is therefore closely tied to the success and strategic direction of Novo Nordisk A/S in the global pharmaceutical market.
What Products and Services Does NVOH Offer?
- Invests primarily in American Depositary Receipts (ADRs) of Novo Nordisk A/S (B Shares).
- Provides investors with exposure to the financial performance of Novo Nordisk A/S.
- Operates as a non-diversified fund, concentrating its investments in a single company.
- Offers a targeted investment strategy focused on the healthcare sector.
- Tracks the performance of Novo Nordisk A/S in the global pharmaceutical market.
- Allows investors to participate in Novo Nordisk's growth without directly purchasing its shares.
How Does NVOH Make Money?
- Generates revenue through investment in Novo Nordisk A/S ADRs.
- Fund performance is directly tied to the market value of Novo Nordisk's shares.
- Manages assets on behalf of investors seeking exposure to Novo Nordisk.
What Industry Does NVOH Operate In?
Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged operates within the healthcare sector, specifically the pharmaceutical industry. This sector is characterized by high research and development costs, stringent regulatory oversight, and intense competition. NVOH's success depends heavily on Novo Nordisk's ability to compete effectively in this landscape, particularly in the diabetes care market, where it holds a significant position. Competitors include other major pharmaceutical companies developing and marketing diabetes treatments and related therapies.
Who Are NVOH's Key Customers?
- Institutional investors seeking exposure to Novo Nordisk A/S.
- Retail investors interested in the healthcare sector and pharmaceutical industry.
- Investors looking for a targeted investment strategy focused on a single company.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
NVOH Financials
Bull Case vs Bear Case
Bull Case
- Focused investment strategy.
- Exposure to a leading global healthcare company.
- Potential for high returns based on Novo Nordisk's performance.
- Upcoming: Clinical trial results for Novo Nordisk's new drug candidates.
Bear Case
- Non-diversified nature increases risk.
- Performance is entirely dependent on a single company.
- Susceptible to regulatory and market risks affecting Novo Nordisk.
- Potential: Patent expirations and biosimilar competition affecting Novo Nordisk's revenue.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NVOH Latest News
No recent news available for NVOH.
NVOH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NVOH.
Price Targets
Wall Street price target analysis for NVOH.
NVOH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NVOH; grades run from A+ (80-100) to F (below 30).
What Investors Ask About Precidian ETFs Trust - Novo Nordisk A/S (B Shares) ADRhedged (NVOH) — Healthcare
What do analysts say about NVOH stock?
As of 2026-03-17, AI analysis for NVOH is pending. However, the fund's performance is intrinsically tied to the performance of Novo Nordisk A/S.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The fund's performance is highly dependent on the performance of Novo Nordisk A/S.